logo
Plus   Neg
Share
Email

LendingTree Sees 29% - 34% Growth In FY19 Revenue Over Midpoint 2018 Guidance

LendingTree Inc. (TREE) said that it expects revenue for full-year 2019 to be in the range of $990 million - $1.030 billion, representing growth of 29% - 34% over the midpoint of full-year 2018 revenue guidance of $765 million - $775 million. Analysts polled by Thomson Reuters expect the company to report revenues of $1.04 billion for fiscal year 2019. Analysts' estimates typically exclude special items.

Variable Marketing Margin is anticipated to be $365 million - $385 million.

Adjusted EBITDA is anticipated to be in the range of $195 million - $205 million, up 27% - 34% over the midpoint of full-year 2018 Adjusted EBITDA guidance of $152 million - $155 million.

"2018 has been another record setting year at LendingTree, and we are thrilled with what we've accomplished this year despite a difficult environment for the mortgage industry" said Doug Lebda, Chairman and CEO.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT